GondolaBio and n-Lorem Foundation Partner to Advance ASOs for Genetic Diseases

Rare Daily Staff

Clinical-stage biotech GondolaBio entered into a collaboration with the non-profit n-Lorem Foundation to jointly discover antisense oligonucleotide therapeutics for two prespecified biological targets for genetic diseases with significant unmet need.

n-Lorem will use its ASO discovery platform and significant expertise in ASO technology to discover, screen, and select ASO medicines for two prespecified biological targets in genetic diseases with significant unmet needs.

Upon selection, any resulting therapies will be clinically and commercially developed by GondolaBio’s subsidiary companies housing the corresponding drug development programs. The two subsidiaries represent the seventh and eighth GondolaBio has formed in its first three months of operation. The company is seeking additional programs in genetically defined diseases.

GondolaBio will provide n-Lorem an upfront payment and research and development expenses. n-Lorem could receive additional payments for each ASO that is discovered and developed by the collaboration.

“At n-Lorem, we have industrialized the treatment of nano-rare patients and created an organization capable of scaling up to meet a growing demand while maintaining high-quality at each step,” said Stanley Crooke, chairman, founder, and CEO of n-Lorem. “The funding we receive from these transactions will enable us to broaden our investment in nano-rare patients and create opportunities for sustainable revenues through potential milestone payments and equity as these programs advance.”

Founded in 2024, GondolaBio is backed with $300 million from investors, including Patient Square Capital, Viking Global Investors, and Frazier Life Sciences. GondolaBio started with three subsidiary companies spun out of BridgeBio Pharma in September, and now with the n-Lorem collaboration, has eight total subsidiaries each housing one drug development program.

Photo: Stanley Crooke, chairman, founder, and CEO of n-Lorem